Corrigendum to “Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches” [Lung Cancer 106 (2017) 70–75](S016950021730034X)(10.1016/j.lungcan.2017.02.002)

J. Remon; N. Pardo; A. Martinez-Martí; S. Cedrés; A. Navarro; A. M. Martinez de Castro; E. Felip

doi:10.1016/j.lungcan.2017.11.007

Corrigendum to “Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches” [Lung Cancer 106 (2017) 70–75](S016950021730034X)(10.1016/j.lungcan.2017.02.002)

J. Remon, N. Pardo, A. Martinez-Martí, S. Cedrés, A. Navarro, A. M. Martinez de Castro, E. Felip

Résultats de recherche: Contribution à un journal › !!Comment/debate

1 Citation (Scopus)

Résumé

The authors regret the below error section ‘2.3. Atezolizumab, avelumab and durvalumab’ of the above referenced paper. The sentence ‘The ongoing phase III MYSTIC trial (NCT02453282) compares durvalumab with or without ipilimumab versus first-line platinum-based chemotherapy.’ Should read ‘The ongoing phase III MYSTIC trial (NCT02453282) compares durvalumab with or without tremelimumab versus first-line platinum-based chemotherapy.’ The authors would like to apologise for any inconvenience caused.

langue originale	Anglais
Pages (de - à)	80
Nombre de pages	1
journal	Lung Cancer
Volume	117
Les DOIs	https://doi.org/10.1016/j.lungcan.2017.11.007
état	Publié - 1 mars 2018
Modification externe	Oui

Accès au document

10.1016/j.lungcan.2017.11.007

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Remon, J., Pardo, N., Martinez-Martí, A., Cedrés, S., Navarro, A., Martinez de Castro, A. M., & Felip, E. (2018). Corrigendum to “Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches” [Lung Cancer 106 (2017) 70–75](S016950021730034X)(10.1016/j.lungcan.2017.02.002). Lung Cancer, 117, 80. https://doi.org/10.1016/j.lungcan.2017.11.007

@article{0f3cade77ec64446be43238840f97e61,

title = "Corrigendum to “Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches” [Lung Cancer 106 (2017) 70–75](S016950021730034X)(10.1016/j.lungcan.2017.02.002)",

abstract = "The authors regret the below error section {\textquoteleft}2.3. Atezolizumab, avelumab and durvalumab{\textquoteright} of the above referenced paper. The sentence {\textquoteleft}The ongoing phase III MYSTIC trial (NCT02453282) compares durvalumab with or without ipilimumab versus first-line platinum-based chemotherapy.{\textquoteright} Should read {\textquoteleft}The ongoing phase III MYSTIC trial (NCT02453282) compares durvalumab with or without tremelimumab versus first-line platinum-based chemotherapy.{\textquoteright} The authors would like to apologise for any inconvenience caused.",

author = "J. Remon and N. Pardo and A. Martinez-Mart{\'i} and S. Cedr{\'e}s and A. Navarro and {Martinez de Castro}, {A. M.} and E. Felip",

note = "Publisher Copyright: {\textcopyright} 2017 Elsevier B.V.",

year = "2018",

month = mar,

day = "1",

doi = "10.1016/j.lungcan.2017.11.007",

language = "English",

volume = "117",

pages = "80",

journal = "Lung Cancer",

issn = "0169-5002",

}

Remon, J, Pardo, N, Martinez-Martí, A, Cedrés, S, Navarro, A, Martinez de Castro, AM & Felip, E 2018, 'Corrigendum to “Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches” [Lung Cancer 106 (2017) 70–75](S016950021730034X)(10.1016/j.lungcan.2017.02.002)', Lung Cancer, VOL. 117, p. 80. https://doi.org/10.1016/j.lungcan.2017.11.007

Corrigendum to “Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches” [Lung Cancer 106 (2017) 70–75](S016950021730034X)(10.1016/j.lungcan.2017.02.002). / Remon, J.; Pardo, N.; Martinez-Martí, A. et al.
Dans: Lung Cancer, Vol 117, 01.03.2018, p. 80.

Résultats de recherche: Contribution à un journal › !!Comment/debate

TY - JOUR

T1 - Corrigendum to “Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients

T2 - Current status and future approaches” [Lung Cancer 106 (2017) 70–75](S016950021730034X)(10.1016/j.lungcan.2017.02.002)

AU - Remon, J.

AU - Pardo, N.

AU - Martinez-Martí, A.

AU - Cedrés, S.

AU - Navarro, A.

AU - Martinez de Castro, A. M.

AU - Felip, E.

PY - 2018/3/1

Y1 - 2018/3/1

N2 - The authors regret the below error section ‘2.3. Atezolizumab, avelumab and durvalumab’ of the above referenced paper. The sentence ‘The ongoing phase III MYSTIC trial (NCT02453282) compares durvalumab with or without ipilimumab versus first-line platinum-based chemotherapy.’ Should read ‘The ongoing phase III MYSTIC trial (NCT02453282) compares durvalumab with or without tremelimumab versus first-line platinum-based chemotherapy.’ The authors would like to apologise for any inconvenience caused.

AB - The authors regret the below error section ‘2.3. Atezolizumab, avelumab and durvalumab’ of the above referenced paper. The sentence ‘The ongoing phase III MYSTIC trial (NCT02453282) compares durvalumab with or without ipilimumab versus first-line platinum-based chemotherapy.’ Should read ‘The ongoing phase III MYSTIC trial (NCT02453282) compares durvalumab with or without tremelimumab versus first-line platinum-based chemotherapy.’ The authors would like to apologise for any inconvenience caused.

UR - http://www.scopus.com/inward/record.url?scp=85041605140&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2017.11.007

DO - 10.1016/j.lungcan.2017.11.007

M3 - Comment/debate

C2 - 29398170

AN - SCOPUS:85041605140

SN - 0169-5002

VL - 117

SP - 80

JO - Lung Cancer

JF - Lung Cancer

ER -

Remon J, Pardo N, Martinez-Martí A, Cedrés S, Navarro A, Martinez de Castro AM et al. Corrigendum to “Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches” [Lung Cancer 106 (2017) 70–75](S016950021730034X)(10.1016/j.lungcan.2017.02.002). Lung Cancer. 2018 mars 1;117:80. doi: 10.1016/j.lungcan.2017.11.007